Secukinumab is under clinical development by Novartis and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Secukinumab’s likelihood of approval (LoA) and phase transition for Skin Rash took place on 16 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Secukinumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Secukinumab (Cosentyx, Zafrez, Fraizeron) is an immunosuppressive agent. It is formulated as freeze-dried preparation for powder for solution and solution in prefilled syringe or pre-filled pen for subcutaneous route of administration. Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy; adult patients with active psoriatic arthritis and with active ankylosing spondylitis. It is also indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation and also indicated for the treatment of psoriasis vulgaris, psoriatic arthritis, and pustular psoriasis in children. Cosentyx (secukinumab), used alone or in combination with methotrexate, in the juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. It is also indicated for the treatment for tendon injury.
Secukinumab is under development for the treatment of pyoderma gangrenosum, patients with active peripheral spondyloarthritis (pSpA), psoriasis, Necrobiosis Lipoidica Diabeticorum, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, giant cell arteritis, atopic dermatitis and ichthyosis, lichen planus, lupus nephritis, non-alcoholic fatty liver disease. The drug candidate was under development for the treatment of atopic dermatitis, alopecia areata, contact dermatitis, moderate-to-severe plaque psoriasis in pediatrics, rheumatoid arthritis, bronchial asthma, non-infectious uveitis in patients with Behcet’s disease, neutrophilia, dry eye syndrome, thyroid eye disease (Graves ophthalmopathy), type 1 diabetes, severe Crohn's disease and relapsing-remitting multiple sclerosis (RRMS), chronic cutaneous lupus erythematosus, relapsing multiple sclerosis and severe acute respiratory syndrome (SARS) associated with Covid-19 and Covid-19 associated pneumonia.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View Secukinumab LOA Data
|Highest Development Stage|